Peptide Science
Peptide Science

Coming Off: The Washout Window

03 mai 2026
washoutcyclingdiscontinuationreboundoff-cycle

Most peptide protocols are written from the on-cycle side: doses, timing, what to expect during the run. The washout - the off-cycle stretch between runs - gets less attention. That's where most of the community's bad decisions get made: panic-restarts when natural variation looks like "the protocol stopped working," doubling-up when a bloodwork result drifts during the natural return-to-baseline, and abandonment of cycle discipline because the off-cycle felt unnecessary. This article covers what actually happens during a washout, by class, so the off-cycle is part of the protocol rather than a gap in it.

For the on/off rationale and why cycling matters in the first place, see Cycling Strategies. For the GLP-1-specific muscle-preservation framing during taper, see GLP-1 and Muscle Preservation.

What "washout" means and what it's for

Washout is the off-period between cycles. Two purposes. First, receptor recovery - chronically stimulated receptors downregulate; an off-period lets receptor density and sensitivity reset. Second, cumulative exposure management - for compounds with long-horizon risks (angiogenic peptides, supraphysiologic IGF-1), intermittent exposure is meaningfully different from continuous exposure on the risk axis.

Washout is not the same as "the compound is gone from your system." Most peptides have plasma half-lives of hours; they're cleared in a day or two. The washout window is the time it takes the downstream signalling to return to baseline - IGF-1 levels, receptor expression, immune tone, satiety set-point. That can be days for some classes and weeks for others.

Per-class washout expectations

GH-axis (Mod GRF, Ipamorelin, Sermorelin, CJC-1295, Tesamorelin)

  • IGF-1 return-to-baseline: 4–6 weeks after the last dose, typically. The pulsatile-GHRH stack architecture leaves the pituitary axis intact, so recovery is a downward drift rather than a rebound.
  • What you'll feel: recovery between training sessions returns to pre-cycle baseline at week 2–4. Sleep depth drifts back. No "withdrawal" pattern; just gradual loss of the on-cycle signal.
  • Bloodwork timing: draw IGF-1 at week 4–6 of washout to confirm return-to-baseline. If IGF-1 stays elevated past 8 weeks, that's worth investigating with a clinician.
  • Body comp: any modest gains (improved sleep-driven recovery, slightly better lean mass retention) hold for weeks but drift back over months without the signal. The cycle was the contribution, not the maintenance.

Continuous-elevation (CJC-1295 DAC, somatropin)

  • IGF-1 return-to-baseline: longer - 6–10 weeks for DAC-CJC, 4–6 for somatropin. The DAC chain extends GH elevation past the dosing window, so the signal lingers further.
  • Recovery question is real for somatropin. Long high-dose somatropin runs can transiently suppress endogenous GH pulse architecture. Recovery to pre-cycle pulsatile output happens but takes months in some users. Sermorelin or Mod GRF + Ipamorelin bridge protocols are sometimes used for users who ran high-dose somatropin for extended periods; not the default for short cycles.
  • Body-comp drift: faster than pulsatile-stack coming-off because the on-cycle effect was larger. The first 8–12 weeks post-cycle are when most of the visible regression happens.

GLP-1 family (Semaglutide, Tirzepatide, Retatrutide, Liraglutide)

  • Half-life and lingering effect: for the long-acting weekly compounds (semaglutide ~7d, tirzepatide ~5d, retatrutide ~6d), measurable serum levels persist 4–6 weeks. Appetite suppression fades on a similar timeline.
  • Appetite rebound is real. The "food noise gets loud again" reports start at week 3–5 for most users. The body's set-point hasn't moved; only the signal that suppressed it has.
  • Weight regain. The most-studied finding from STEP discontinuation trials: roughly two-thirds of cut weight returns within 12 months of stopping if no maintenance protocol is in place. This is the load-bearing data point - taper to ~50% of cutting dose for 6–12 months before discontinuing entirely is the community discipline. See GLP-1 and Muscle Preservation for muscle-loss specifics during the same window.
  • Bloodwork: HbA1c and fasting glucose may drift upward in 4–8 weeks if no metabolic foundation work was done during the on-cycle. The cycle didn't change baseline glucose tolerance, only masked it.

Growth factor class (IGF-1 LR3, IGF-1 DES, PEG-MGF)

  • 4-week blast → 4-week washout is the standard discipline. After a 4-week LR3 blast, IGF-1 returns to baseline in 2–3 weeks; receptor sensitivity recovers over the full 4-week off-period.
  • Hypoglycemia risk gone within days. The acute safety profile resolves quickly once dosing stops; the long-horizon growth-pathway risk is what cycling is actually managing.
  • Body comp drift: any visible muscle-mass gain holds for weeks but the rate of acquisition stops. LR3 was the accelerator; without it, you're back to AAS-and-training pace.

Healing peptides (BPC-157, TB-500, GHK-Cu systemic)

  • Cycle is for an injury or procedure window. Washout is the rest of the year. There's no on-cycle effect to maintain because the cycle was a tool for a specific repair window that's now closed.
  • What you might notice: small joint or tendon discomfort that the on-cycle was masking can resurface. That's a signal the underlying condition wasn't fully resolved, not a "withdrawal" from the peptide.
  • Cumulative-exposure framing applies. The angiogenic load from BPC + TB-500 is intermittent rather than continuous, which is the protective design of the cycle. See Cancer Risk and Growth Factors.

Melanocortin (Melanotan II, PT-141)

  • MT-II pigment persists. The acquired tan from a loading + maintenance cycle holds for months. There's no rapid fade-back because melanin in melanocytes is the storage; UV exposure during washout maintains it longer than expected.
  • Side effects fade fast. Nausea, flushing, spontaneous erection effects all resolve within days of stopping. The cycle was titrated to tolerance; off-cycle resets the tolerance.
  • PT-141 has no real washout - it's used on-demand, not chronically. "Stopping" PT-141 just means not using it; no discontinuation effect.

Cognitive (Selank, Semax)

  • No withdrawal pattern. Stop using the spray; the effect fades over the next 24 hours and that's it. No rebound anxiety, no rebound brain fog.
  • Selank's situational effect remains accessible. Chronic use can blunt the situational dose; an off-period restores responsiveness within 2 weeks. This is one of the few peptides where washout actively makes the on-cycle better.

What to track during washout

  • IGF-1 + HbA1c at weeks 4–8 if you ran a GH-axis, growth-factor, or supraphysiologic-IGF protocol. Confirms the return-to-baseline; flags any persistent drift.
  • Body weight, weekly. Especially important for GLP-1 washouts where the regain pattern is well-studied. Tracking the rate of regain (gradual vs sharp) tells you whether the foundation work during on-cycle stuck.
  • Sleep tracker (RHR, deep sleep). GH-axis cycles show their loss most cleanly in sleep tracker data - RHR drifts upward 2–4 bpm and deep-sleep fraction drops over 2–4 weeks. That's expected, not a problem.
  • Subjective journal. Mood, motivation, recovery quality. The signal is noisier than bloodwork but catches things that don't move objective markers.
  • Resting BP for melanocortin runs. Confirms return to pre-cycle baseline; flags any persistent drift.

Common washout mistakes

  • Panic-restarting at week 3. The "I lost the benefit overnight" framing is almost always reading natural week-to-week variation as cycle loss. The washout is the protocol; finishing it is the protocol. Re-starting before the receptor recovery happens defeats the purpose of cycling.
  • Doubling up the next cycle to "make up" for the washout. The next cycle should be the same dose as the last successful one, not double. Cumulative-exposure risk doesn't care about the per-cycle effort to compensate; it tracks total drug-time integrated over weeks.
  • Discontinuing a GLP-1 cold-turkey from cutting dose. The taper to maintenance is the protocol, not the afterthought. Roughly 60% of cut weight regained within 12 months is the discontinuation-trial finding. Plan for the maintenance phase before the cut.
  • Skipping bloodwork during washout. The off-cycle is when you confirm reversibility. If IGF-1 stays elevated, HbA1c keeps drifting, or hematocrit doesn't normalise, that's data you need before the next cycle. Skipping it loses the most informative bloodwork window.
  • Treating off-cycle as "wasted time." The off-cycle is when the receptor density returns, the tissue repairs from on-cycle stress, and your body's natural endocrine rhythms reset. For protocols where on-cycle has accumulated load (somatropin suppression, IGF-1 supraphysiologic exposure, melanocortin autonomic load), the off-cycle is doing real work even when it feels like nothing's happening.

Decision frame for re-starting

  1. Has the off-cycle reached its planned duration?
    → No → finish it. Don't restart early without a specific reason.
    → Yes → continue.
  2. Did bloodwork drift back to baseline?
    → Yes → safe to restart at the previous dose.
    → No → extend the washout 2–4 weeks; re-test.
  3. Is there a clinical reason to restart now (acute injury, upcoming competition, etc.)?
    → Yes → coordinate the restart timing around the trigger; consider whether a different compound class fits the new context.
    → No → restart on the original schedule.
  4. Are you restarting because you "miss the feeling" rather than for an objective reason?
    → That's a flag to extend the washout, not shorten it. The feeling-of-missing-it pattern is what receptor downregulation is designed to manage; restarting earlier compounds the underlying issue.

Cross-references